Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined
with the immunoadjuvant imiquimod is safe and can induce immune responses in children with
recurrent ependymomas. Eligible patients are stratified by primary tumor location.
Phase:
Phase 1
Details
Lead Sponsor:
Ian F. Pollack, M.D. University of Pittsburgh
Collaborators:
National Cancer Institute (NCI) Solving Kids' Cancer Solving Kids’ Cancer